";s:4:"text";s:4527:" Learn everything you need to know about successful options trading with this three-part video course.Looking for new stock ideas? Imugene Limited is an immuno-oncology focused biopharmaceutical company. Export data to Excel for your own analysis. These stocks have paid out triple-digit gains… On the same date… Year after year — for the last decade (look at this week's Primetime Stock here).Imugene Limited, an immuno-oncology biopharmaceutical company, develops mimotopes and small molecule drug candidates in Australia. Jeff Brown is a member of the U.S. Chamber of Digital Commerce... Its lead product is HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu receptors, which are expressed on the surface of tumors, including gastric, breast, ovarian, and pancreatic cancers. See what's happening in the market right now with MarketBeat's real-time news feed. The Company is also developing mimotope-based immunotherapies against validated and oncology targets. In addition, the highly experienced Viralytics OV team will join IMU to further boost the $68.5 million capped company’s OV research and trials — certainly good news for IMU and its shareholders. Fund performance data provided by Lipper. Learn about financial terms, types of investments, trading strategies and more.MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. The Company is engaged in the research and development of human epidermal growth factor receptor 2 positive (HER2 +ve), and gastric and breast cancer vaccines. The Company is also engaged in the research, development and commercialization of health technologies. Learn everything you need to know about successful options trading with this three-part video course.Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:You have already added five stocks to your watchlist.
Recent Comments